Collection of Circulating Biomarkers in Pancreatic Cancer

April 2, 2026 updated by: Abramson Cancer Center at Penn Medicine

Protocol to Permit Collection of Circulating Biomarkers in Pancreatic Cancer

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Abramson Cancer Center at University of Pennsylvania

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

known or suspected diagnosis of pancreatic adenocarcinoma

Description

Inclusion Criteria:

  • The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma
  • The subject must be a patient of the University of Pennsylvania
  • The subject must be able to provide informed consent
  • The subject must be 18 years of age or older

Exclusion Criteria:

. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Blood specimens
Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.
Other: Obtaining blood for analysis of various circulating biomarkers
4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.
Time Frame: Through study completion, an average of 1 year
Through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.
Time Frame: Through study completion, an average of 1 year
Through study completion, an average of 1 year
To integrate the data and specimens to permit the most informative clinical-biologic research platform.
Time Frame: Through study completion, an average of 1 year
Through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Abramson Cancer Center at Penn Medicine

Investigators

  • Principal Investigator: Mark O'Hara, MD, Abramson Cancer Center, University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 27, 2023

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

January 15, 2028

Study Registration Dates

First Submitted

February 10, 2023

First Submitted That Met QC Criteria

February 22, 2023

First Posted (Actual)

February 24, 2023

Study Record Updates

Last Update Posted (Actual)

April 7, 2026

Last Update Submitted That Met QC Criteria

April 2, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UPCC 20222
  • 852628 (Other Identifier: University of Pennsylvania IRB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreas Cancer

Clinical Trials on Obtaining blood for analysis of various circulating biomarkers

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe